Premarin Articles
Pfizer fights back on HRT and cancer links highlighted by NYT
14 December 2009
Wyeth's first-quarter 2009 profit flat year-on-year as it prepares for Pfizer mega-merger
29 April 2009
Wyeth's 3rd-qtr profit flat; AD drug delayed
3 November 2008
$27M damages thrown out for Wyeth/Upjohn
21 July 2008
Wyeth beats forecasts despite generics
5 May 2008
Wyeth to pay $134.5 M in HR law suit
22 October 2007
Wyeth wins Philadelphia HRT trial
21 May 2007
Duramed's Enjuvia gets two FDA appros
7 May 2007
UK study links HRT to ovarian cancer
30 April 2007
Wyeth hormone law suit dismissed
12 February 2007
Wyeth reports strong Ph II data on TSECs
6 November 2006
Wyeth unveils seven late-stage drugs for 11 indications at its annual R&D presentation
16 October 2006
Jury finds in Wyeth favor in HRT case
25 September 2006
Wyeth's 1st-qtr 2006 revenues $4.8B, up 6%
1 May 2006
Wyeth study: conjugated estrogen does not pose breast cancer risk, in some cases shows benefit
24 April 2006
Stock Commentary - New York week to April 17, 2006
24 April 2006
No link between Premarin and CHD
27 February 2006
USA
22 August 2005
Barr's Bijuva gets non-approvable letter from US FDA
28 April 2005
Wyeth prevails in Natural Biologics case
31 January 2005
Barr's Duramed acquires exclusive rights to Nordette
10 January 2005
US uninsured "pay 78% more than best Rx prices"
1 November 2004
Solvay awarded $68 million in Barr dispute
28 June 2004
NIH researchers terminate ostrogen study
15 March 2004
Stock Commentary - New York
8 March 2004
Charges pull Wyeth earnings down 79%
2 February 2004
Stock Commentary - New York
2 February 2004
Barr to acquire Endeavor Pharma assets
15 December 2003
Wyth sees 3rd-quarter loss on charges
27 October 2003
Wyeth secrets were stolen, says judge
22 September 2003
Wyeth's low-dose Prempro launched
7 July 2003
FDA approves Wyeth's low-dose Prempro
16 June 2003
Profits up at Wyeth, HRT sales still suffering
28 April 2003
FDA OKs Wyeth's low-dose Prempro
24 March 2003
Prempro may worsen cognition; new study
10 March 2003
Earnings up at Wyeth, HRT drugs sluggish
3 February 2003
US FDA tells women:
20 January 2003
Stock Commentary - New York
29 July 2002
Wyeth EPS increases 25% during 2nd qtr
29 July 2002
Prempro fall-out could affect Schering AG
22 July 2002
Wyeth hit as Prempro linked to cancer, CVD
15 July 2002
Wyeth's bazedoxifene on market by 2006?
8 July 2002
Royalty purchases shares of future Ligand sales
11 March 2002
Barr/Natural Biologics to develop generic Premarin
11 March 2002
AHP overcomes fen-phen problems to post strong growth for 2001
4 February 2002
Barr second-quarter earnings leap on sales of generic Prozac
4 February 2002
Huge leap in net income at Duramed Pharmaceuticals
24 October 2001
Barr acquires Duramed - UPDATE
2 July 2001
New AHP CEO reviews growth strategy
25 May 2001
New drug sales boost AHP's 1st-qtr profits
26 April 2001
US HMOs reveal their most-accepted drugs
5 April 2001
AHP takes $7.5 billion charge for fen-phen
26 January 2001
W-A's Premarin is top US formulary drug
29 November 2000
AHP reaping benefits of R&D spend
20 October 2000
AHP posts healthy 2nd quarter results
24 July 2000
Duramed completes $10 million placement
16 May 2000
Elderly-use drug price rises "above inflation"
28 April 2000
US doctors wrote 9% more scripts last year
25 April 2000
AHP posts 18% net income growth
20 April 2000
Cenestin approved in additional dose
15 March 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
American Home Products confirms merger talks with Warner-Lambert
4 November 1999
World's top-selling drugs; 2002 forecasts
13 August 1999
Duramed launches Cenestin
29 July 1999
Third-party payers lead Rx payments
5 May 1999
Canadian drug spend up 12.7% in 1998
13 April 1999
Duramed looks to Cenestin for growth
6 April 1999
FDA complaints over drug ads viewed
1 April 1999
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
HERS Casts Doubt On HRT Role In Heart Disease
20 August 1998
Duramed Responds To Cenestin Petition
12 August 1998
American Home Pharma Sales Up 7% For 2nd Qtr
22 July 1998
US Generics Sector "Lacks Political Clout"
16 June 1998
Merged AHP/Monsanto Will Be Top US Drugmaker
15 June 1998
US Generics Sector "Lacks Political Clout"
12 June 1998
US Quarterly Financial Results Round-Up
23 April 1998
Duramed To File NDA For Cenestin
2 April 1998
Duramed To File For Conjugated Estrogens
26 February 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
Drug Cos Must Act Now To Ensure Future Prosperity
22 January 1998
New Products In 1998; A Look Ahead
6 January 1998
Duramed Approval
2 January 1998
FDA Approves Raloxifene For Osteoporosis
11 December 1997
Lilly's Evista Backed By US Panel For Osteoporosis
27 November 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
